QSV Equity Investors LLC Acquires 29,197 Shares of Core Laboratories Inc. $CLB

Key Points

• QSV Equity Investors LLC increased its holdings in Core Laboratories Inc. by 49.3%, acquiring 29,197 shares, bringing its total ownership to 88,455 shares valued at $1.326 million.
• Core Laboratories announced a quarterly dividend of $0.01 per share, with a yield of 0.4%, to be paid on August 25th.
• Core Laboratories registered a net margin of 5.73% and reported $130.16 million in revenue for the last quarter, slightly above analysts' expectations.

QSV Equity Investors LLC grew its stake in shares of Core Laboratories Inc. (NYSE:CLB - Free Report) by 49.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 88,455 shares of the oil and gas company's stock after acquiring an additional 29,197 shares during the period. QSV Equity Investors LLC owned about 0.19% of Core Laboratories worth $1,326,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Assetmark Inc. grew its holdings in Core Laboratories by 92.5% during the 1st quarter. Assetmark Inc. now owns 2,887 shares of the oil and gas company's stock worth $43,000 after acquiring an additional 1,387 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Core Laboratories by 843.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,284 shares of the oil and gas company's stock worth $57,000 after acquiring an additional 2,936 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in Core Laboratories during the 4th quarter worth $123,000. XTX Topco Ltd acquired a new position in Core Laboratories during the 1st quarter worth $155,000. Finally, Sherbrooke Park Advisers LLC acquired a new position in Core Laboratories during the 4th quarter worth $176,000. 97.81% of the stock is owned by institutional investors and hedge funds.

Core Laboratories Price Performance

NYSE:CLB traded up $0.6750 during mid-day trading on Friday, reaching $11.1350. 509,926 shares of the company were exchanged, compared to its average volume of 481,593. Core Laboratories Inc. has a 12 month low of $9.72 and a 12 month high of $21.83. The company has a fifty day moving average of $11.57 and a 200 day moving average of $12.79. The company has a quick ratio of 1.70, a current ratio of 2.27 and a debt-to-equity ratio of 0.47. The stock has a market cap of $522.12 million, a PE ratio of 17.96, a PEG ratio of 3.16 and a beta of 1.41.

Core Laboratories (NYSE:CLB - Get Free Report) last released its earnings results on Wednesday, July 23rd. The oil and gas company reported $0.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.18 by $0.01. The company had revenue of $130.16 million for the quarter, compared to the consensus estimate of $129.19 million. Core Laboratories had a net margin of 5.73% and a return on equity of 14.15%. The company's revenue was down .3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.22 EPS. Core Laboratories has set its Q3 2025 guidance at 0.180-0.220 EPS. On average, research analysts anticipate that Core Laboratories Inc. will post 0.96 EPS for the current fiscal year.

Core Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 25th. Stockholders of record on Monday, August 4th will be issued a $0.01 dividend. The ex-dividend date is Monday, August 4th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.4%. Core Laboratories's dividend payout ratio (DPR) is 6.45%.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on CLB. Citigroup reduced their target price on shares of Core Laboratories from $16.00 to $13.00 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. Zacks Research raised shares of Core Laboratories from a "strong sell" rating to a "hold" rating in a research report on Friday, August 15th. Wall Street Zen raised shares of Core Laboratories from a "sell" rating to a "hold" rating in a research report on Saturday, July 26th. Finally, Stifel Nicolaus decreased their target price on shares of Core Laboratories from $13.00 to $12.00 and set a "hold" rating for the company in a research report on Wednesday, July 16th. Three equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $12.50.

Core Laboratories Company Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.